HONG KONG, December 8, 2025 – As China positions the bioeconomy and life sciences as pillars of its upcoming 15th Five-Year Plan (2026–2030), Hong Kong–listed Regent Pacific Group (0575.HK) says the policy momentum is creating favourable conditions for the rapid expansion of AI-enabled longevity technologies.
In a recent conversation with AsiaBizToday, Jamie Gibson, Executive Director and CEO of Regent Pacific, outlined why the company believes its wholly owned subsidiary Deep Longevity—a specialist in AI-powered aging clock technologies—is well placed to benefit from demographic shifts, rising demand for preventive healthcare, and cross-border data reforms.
Ageing Population Driving New Demand for Predictive Health Technologies
Gibson said China’s commitment to developing “future-oriented industries” such as life and health technologies, biomanufacturing and AI is creating an enabling environment for companies operating in the longevity and wellness technology space.
“The momentum behind the bioeconomy offers a very exciting backdrop for companies like Deep Longevity,” he said, noting that global wellness is already a US$6.8 trillion market and is shifting rapidly toward personalised, preventive and data-driven health solutions.
Deep Longevity has commercialised a suite of AI-driven aging clocks—including BloodAge, MindAge, BiometricAge and EpigeneticAge—that analyse biomarkers, epigenetics, psychological data and biometric signals to assess an individual’s biological age. Gibson said these tools allow users to determine whether they are ageing faster or slower than their chronological age and to take targeted action to extend health-span.
Strategic Roadmap: New Clocks, Global Markets and Enterprise-Scale SaaS
Regent Pacific is now focusing on expanding Deep Longevity’s product pipeline and global reach.
Key priorities include:
- Developing new aging clocks for beauty, skin health, microbiome analysis, facial ageing and organ-specific metrics.
- Scaling its enterprise SaaS platforms (SenoClock and SenoClock Gold) for insurers, employers, diagnostic labs, wellness providers and health systems.
- Building regional presence across Greater China, Hong Kong, the U.S., Southeast Asia and the Middle East through partnerships with clinics, wellness operators and research institutions.
- Strengthening AI/ML, biomarker science and IP to maintain leadership in aging-clock innovation.
“In this context, we are well positioned to capitalise on the convergence of biotechnology, data science, preventive health and the ageing economy—areas strongly aligned with China’s strategic development priorities,” Gibson said.
Growing Commercial Adoption Across Healthcare, Wellness and Insurance
Deep Longevity’s aging clocks are already being deployed across several sectors:
- Healthcare and diagnostics: to stratify patients by biological age, identify high-risk individuals and monitor treatment response.
- Corporate wellness programmes: enabling personalised longevity insights, employee health tracking and potential cost reduction for employers.
- Insurance: improving longevity risk modelling and supporting new health-span-linked product designs.
- Medical aesthetics and wellness: where Deep Longevity is developing FaceAge and MicrobiomeAge products as data-driven tools for aesthetic clinics and high-value wellness consumers.
Gibson said Deep Longevity has signed SaaS contracts and pilot arrangements with partners in Asia, the U.S. and the Middle East, integrating biological-age diagnostics into personalised wellness packages, coaching programmes and biometric health monitoring.
The Hong Kong government’s 2025 Policy Address—which prioritises emerging industries such as life and health technology, AI and advanced manufacturing—also reflects growing policy alignment with Deep Longevity’s ambitions.
Gibson said the company plans to expand recruitment in Hong Kong to support platform development, enterprise deployment, and regional commercialisation.
He added that Hong Kong’s intention to enable secure cross-border data flow between the Mainland and the Hetao Shenzhen–Hong Kong Innovation Zone could accelerate R&D and support Mainland-facing commercial deployment.
“Policy alignment increases our ability to engage enterprise customers in the Mainland and monetise ageing-clock technology at scale,” he said.
Longevity Sector Investment Surges Globally
Citing data from the Longevity.Technology 2024 Annual Longevity Investment Report, Gibson highlighted that funding for ageing-intervention technologies reached US$8.49 billion in 2024, more than double the previous year.
He believes the next 3–5 years will be defined by major opportunities in:
- biomarkers and preventive-care diagnostics
- beauty and consumer wellness convergence
- enterprise SaaS-based longevity platforms
- AI/ML-driven ageing analytics
- Asia’s under-penetrated but fast-expanding longevity market
“We see the ageing-clock sector as a high-growth, multi-vertical opportunity. Deep Longevity is intentionally built to capture this convergence,” Gibson said.
China and the U.S. Identified as Deep Longevity’s Core Growth Markets
As part of its commercial build-out, Deep Longevity has recently hired two senior U.S.-based executives to spearhead its entry into the American market in 2026—an expansion Gibson described as a “major growth driver” for the company.
He added that China and the U.S. remain Deep Longevity’s two most important development markets, combining demographic need with large customer bases across healthcare, wellness, medical aesthetics, insurance and diagnostics.
Positioning for a Data-Driven Longevity Future
Looking ahead, Gibson said Regent Pacific will continue focusing on technologies that extend healthy lifespan, improve quality of life and support early-stage intervention for age-related conditions.
With China’s policy emphasis on the bioeconomy and Hong Kong’s integration with Mainland innovation ecosystems, the company sees a strong long-term pathway for AI-enabled aging clocks to become mainstream tools in diagnostics, wellness optimisation and preventive healthcare.
As ageing accelerates across Asia and worldwide, the convergence of biotechnology, digital health and artificial intelligence is poised to reshape how individuals, employers and healthcare systems understand and manage human longevity.